Ethics and dissemination

The trial complies with the Declaration of Helsinki and GCP guidelines. All eligible, willing participants will undergo full written informed consent by GCP-trained staff before taking any part in the study. All protocol modifications will be reviewed by the study sponsor and communicated to relevant parties once approved.

The results will be applicable and of interest to emergency physicians, paramedics, acute physicians, NHS Trusts, general practitioners, emergency care practitioners and patients and efforts will be made to disseminate the information to all of these groups. To that end, the study will be submitted for publication in international, high impact, peer-reviewed journals whose target audience includes appropriate clinicians. Results will also be shared with the HHT foundation and telangiectasia UK (patient groups at significant risk of epistaxis) for publication on their websites and presentation through appropriate related forums. After the end of the study, information collected during the study may be made available as an anonymised participant-level dataset to other researchers under an appropriate data sharing agreement.